Physician profile
Timothy M Henschel
NPI 1568576775
$1,817.61
in general payments reported to CMS, 2019-2025
23 companies · $497 in 2025
The $497 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $109 · 2021: $53.53 · 2022: $228 · 2023: $324 · 2024: $481 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $807.18 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $166.64 | 2021-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $90.70 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Tris Pharma INC | $86.74 | 2020-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $85.06 | 2019-2023 | Gattex |
| Glaxosmithkline, LLC. | $77.79 | 2022-2025 | Bexsero, Pediarix |
| Supernus Pharmaceuticals, INC. | $75.41 | 2021-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $59.83 | 2019 | |
| Collegium Pharmaceutical, INC. | $59.47 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $50.29 | 2022-2023 | Cotempla Xr-Odt |
| Avion Pharmaceuticals | $30.91 | 2023 | Methylphenidate Hydrochloride |
| Sanofi Pasteur INC. | $27.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.81 | 2019 | |
| Cipher Pharmaceuticals US LLC | $21.15 | 2025 | Natroba, Spinosad |
| Noven Therapeutics, LLC | $20.08 | 2025 | Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.58 | 2025 | |
| Sobi, INC | $19.27 | 2020 | |
| Pfizer INC. | $18.66 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.32 | 2024 | Relexxii |
| Adlon Therapeutics L.P. | $16.77 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $16.54 | 2025 | Neffy |
| Cranial Technologies, INC | $14.76 | 2025 | Doc Band |
| Kaleo, INC. | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Henschel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.